Synaptic Transmission

Synaptic Transmission

Overview

Synaptic transmission is the fundamental process by which neurons communicate, converting electrical signals (action potentials) into chemical signals (neurotransmitter release) across the 20–40 nm synaptic cleft. The human brain contains approximately 100 trillion synapses, each capable of transmitting signals within 0.5–5 milliseconds with extraordinary fidelity and plasticity. In neurodegenerative diseases, synaptic dysfunction is increasingly recognized as the earliest pathological event — preceding neuronal death by years to decades — and correlating more strongly with cognitive decline than either amyloid plaques or neurofibrillary tangles in Alzheimer's disease[@terry1991].

Presynaptic Mechanisms

The Synaptic Vesicle Cycle

Neurotransmitter release requires the precisely orchestrated cycling of synaptic vesicles through distinct functional pools[@sudhof2012]:

Vesicle pools: The reserve pool (RP, ~80% of vesicles) is tethered to the actin cytoskeleton via synapsin and mobilized during sustained activity. The recycling pool (~15%) maintains transmission during moderate activity. The readily releasable pool (RRP, ~5%, 5–20 vesicles per active zone) is docked and primed at the active zone for immediate release upon calcium entry.

Synaptic Transmission

Overview

Synaptic transmission is the fundamental process by which neurons communicate, converting electrical signals (action potentials) into chemical signals (neurotransmitter release) across the 20–40 nm synaptic cleft. The human brain contains approximately 100 trillion synapses, each capable of transmitting signals within 0.5–5 milliseconds with extraordinary fidelity and plasticity. In neurodegenerative diseases, synaptic dysfunction is increasingly recognized as the earliest pathological event — preceding neuronal death by years to decades — and correlating more strongly with cognitive decline than either amyloid plaques or neurofibrillary tangles in Alzheimer's disease[@terry1991].

Presynaptic Mechanisms

The Synaptic Vesicle Cycle

Neurotransmitter release requires the precisely orchestrated cycling of synaptic vesicles through distinct functional pools[@sudhof2012]:

Vesicle pools: The reserve pool (RP, ~80% of vesicles) is tethered to the actin cytoskeleton via synapsin and mobilized during sustained activity. The recycling pool (~15%) maintains transmission during moderate activity. The readily releasable pool (RRP, ~5%, 5–20 vesicles per active zone) is docked and primed at the active zone for immediate release upon calcium entry.

Vesicle docking and priming: Vesicle docking at active zones is organized by the RIM-RIM-BP-Munc13-ELKS protein complex. RIM1/2 scaffold proteins recruit voltage-gated calcium channels (VGCCs) to the active zone, ensuring tight coupling between calcium entry and vesicle fusion. Munc13-1 opens syntaxin-1 from its closed conformation, enabling SNARE complex nucleation. Munc18-1/STXBP1 chaperones syntaxin-1 and templates SNARE complex assembly — STXBP1 mutations cause early infantile epileptic encephalopathy, underscoring its essential role[@sudhof2013].

SNARE-mediated fusion: The core fusion machinery consists of three SNARE proteins that form a four-helix coiled-coil bundle providing the mechanical energy for membrane merger:

• Synaptobrevin-2/VAMP2 (v-SNARE, vesicle membrane)
• Syntaxin-1A (t-SNARE, plasma membrane)
• SNAP-25 (t-SNARE, contributes two helices)

Calcium sensing: Calcium entry through P/Q-type (Cav2.1) and N-type (Cav2.2) VGCCs at the active zone creates a transient microdomain of 10–100 μM calcium within 20–50 nm of docked vesicles. Synaptotagmin-1 (for fast synchronous release) and synaptotagmin-7 (for slow asynchronous release) act as the calcium sensors, binding calcium through their C2A and C2B domains and triggering membrane fusion within 200 microseconds.

Vesicle recycling: After fusion, vesicle membrane and proteins are retrieved through three pathways: (1) clathrin-mediated endocytosis (CME, primary pathway, ~20 seconds), (2) ultrafast endocytosis (~50–100 ms), and (3) kiss-and-run fusion (reversible pore opening). Retrieved vesicles are refilled with neurotransmitter by vesicular transporters (VGLUT1/2, VGAT, VMAT2).

Neurotransmitter Systems

The major neurotransmitter systems affected in neurodegeneration include:

• Glutamate (primary excitatory): Released at ~80% of cortical synapses; acts on AMPA, NMDA, and kainate ionotropic receptors and mGluR metabotropic receptors. Excessive glutamate signaling causes excitotoxicity.
• GABA (primary inhibitory): Released by interneurons; acts on GABAA (ionotropic, Cl⁻ channel) and GABAB (metabotropic) receptors. Interneuron dysfunction contributes to network hyperexcitability in AD[@palop2016].
• Dopamine: Released by dopaminergic neurons; acts on D1-like (D1, D5) and D2-like (D2, D3, D4) receptors. Nigrostriatal dopamine loss drives PD motor symptoms.
• Acetylcholine: Released by cholinergic neurons; acts on nicotinic (ionotropic) and muscarinic (metabotropic) receptors. Basal forebrain cholinergic loss underlies AD cognitive decline.
• Serotonin (5-HT): Released by raphe nuclei; modulates mood, sleep, and cognition. Disrupted early in AD and PD.

Postsynaptic Mechanisms

Postsynaptic Density

The postsynaptic density (PSD) is a ~300 nm disc-shaped electron-dense structure beneath excitatory synapses, containing approximately 1,000 distinct protein species organized in a layered architecture[@sheng2007]:

• Receptor layer: AMPA receptors (GluA1-4 subunits), NMDA receptors (GluN1/GluN2A-D), kainate receptors, and mGluRs.
• Scaffold layer: PSD-95/DLG4 (anchors NMDA receptors), Homer (links mGluRs to IP3 receptors), Shank (master scaffold integrating Homer and PSD-95 families).
• Signaling layer: CaMKII (the most abundant PSD protein, critical for LTP), calcineurin (PP2B, mediates LTD), and SynGAP (Ras-GAP regulating AMPAR trafficking).

Synaptic Plasticity

Long-term potentiation (LTP): Persistent strengthening of synaptic transmission following high-frequency stimulation. The early phase (E-LTP, 1–3 hours) requires CaMKII autophosphorylation and AMPAR insertion into the postsynaptic membrane; the late phase (L-LTP, >3 hours) requires new protein synthesis and structural spine enlargement[@malenka2004].

Long-term depression (LTD): Weakening of synaptic transmission following low-frequency stimulation. mGluR-LTD requires local dendritic protein synthesis and AMPAR endocytosis; NMDAR-LTD is mediated by calcineurin and the ubiquitin-proteasome system.

Synaptic Dysfunction in Neurodegeneration

Alzheimer's Disease

Synapse loss is the strongest correlate of cognitive decline in AD, exceeding the correlation with amyloid plaques, neurofibrillary tangles, or neuronal loss[@selkoe2002].

Aβ oligomer synaptotoxicity: Soluble amyloid-β oligomers bind to synaptic sites through multiple receptors (PrPC, mGluR5, NMDAR, EphB2, LilrB2), triggering pathological cascades: (1) NMDAR internalization reducing LTP, (2) calcineurin-dependent AMPAR endocytosis enhancing LTD, (3) dendritic spine shrinkage and elimination, and (4) tau missorting into the somatodendritic compartment[@bhatt2014].

Tau-mediated synaptic damage: Hyperphosphorylated tau normally confined to axons missorts to dendritic spines, where it interacts with the PSD-95-NMDAR complex, mediating Aβ-driven excitotoxicity. Tau reduction prevents Aβ-induced synaptic dysfunction in transgenic models, establishing tau as a necessary mediator of Aβ synaptotoxicity.

Cholinergic synapse loss: Degeneration of basal forebrain cholinergic projections to the cortex and hippocampus reduces cholinergic tone, impairing attention, memory encoding, and cortical plasticity. Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide modest symptomatic benefit by prolonging synaptic acetylcholine action.

Parkinson's Disease

Dopaminergic synaptic failure: α-Synuclein accumulation at presynaptic terminals disrupts SNARE complex assembly (α-synuclein normally promotes SNARE complex formation), impairs synaptic vesicle clustering, and reduces the readily releasable pool. Dopamine release deficits precede dopaminergic neuron loss, suggesting that synaptic dysfunction drives early PD symptoms[@bhatt2020].

Corticostriatal plasticity disruption: Loss of dopaminergic modulation disrupts bidirectional plasticity at corticostriatal synapses. D1 receptor-bearing direct pathway MSNs lose LTP, while D2 receptor-bearing indirect pathway MSNs lose LTD, creating the circuit imbalance that underlies bradykinesia and rigidity.

Amyotrophic Lateral Sclerosis

Neuromuscular junction denervation: NMJ disassembly is among the earliest pathological events in ALS, following a "dying-back" pattern where distal axon terminals degenerate before motor neuron soma. Fast-fatigable motor units are lost first, followed by fast-fatigue-resistant and finally slow units[@fischer2004].

Cortical hyperexcitability: Transcranial magnetic stimulation studies reveal cortical hyperexcitability in ALS patients, reflecting loss of inhibitory interneuron function and enhanced glutamatergic transmission — providing the rationale for riluzole (glutamate release inhibitor) therapy.

Huntington's Disease

Mutant huntingtin disrupts corticostriatal synaptic transmission through multiple mechanisms: reduced cortical BDNF transport to the striatum (depleting a critical survival/plasticity factor for medium spiny neurons), impaired glutamate uptake by astrocytes (due to reduced GLT-1/EAAT2 expression), and altered NMDAR trafficking and sensitization.

Synaptic Biomarkers in Neurodegeneration

Synaptic biomarkers are emerging as critical tools for early diagnosis and therapeutic monitoring[@bhatt2018]:

• CSF neurogranin: Postsynaptic protein elevated in AD CSF, reflecting dendritic/spine degeneration.
• CSF SNAP-25: Presynaptic SNARE component, elevated in AD.
• CSF synaptotagmin-1: Presynaptic calcium sensor, elevated in AD.
• Synaptic vesicle glycoprotein 2A (SV2A) PET: 11C-UCB-J PET imaging of synaptic density in vivo; reduced in AD hippocampus, PD substantia nigra, and epileptic foci.

Therapeutic Strategies

Current Therapies Targeting Synaptic Transmission

• Memantine: NMDAR open-channel blocker that reduces tonic excitotoxic glutamate signaling while preserving phasic synaptic transmission; approved for moderate-severe AD[@bhatt2017].
• Acetylcholinesterase inhibitors: Donepezil, rivastigmine, galantamine enhance cholinergic synaptic transmission in AD.
• Levodopa: Restores dopaminergic synaptic transmission in PD.
• Riluzole: Inhibits presynaptic glutamate release in ALS.

Emerging Approaches

• SV2A modulators: Levetiracetam and derivatives that modulate synaptic vesicle release probability; trials in AD for network hyperexcitability.
• AMPAR positive allosteric modulators (ampakines): Enhance excitatory synaptic transmission for cognitive enhancement.
• Synaptic organizer therapies: Neurexin-neuroligin pathway modulators to restore synaptic structure.
• BDNF-enhancing strategies: Exercise, 7,8-DHF (TrkB agonist), and gene therapy to restore neurotrophic support[@lu2013].

Synaptic Proteins in Neurodegenerative Diseases

| Protein | Function | Synapse Type | AD Changes | PD Changes | ALS Changes | Therapeutic Target |
|---------|----------|--------------|------------|------------|-------------|-------------------|
| Synapsin | Vesicle cycling | Excitatory | Reduced | Reduced | Reduced | - |
| Synaptophysin | Vesicle protein | All | Reduced | Reduced | Reduced | - |
| SNAP-25 | SNARE complex | Excitatory | Reduced | Reduced | Reduced | Botulinum toxins |
| VAMP2 | SNARE complex | Excitatory | Dysregulated | Dysregulated | - | - |
| PSD-95 | Scaffold protein | Excitatory | Reduced | Reduced | Reduced | - |
| Synaptopodin | Spine scaffold | Excitatory | Reduced | - | - | - |
| VGAT | GABA transporter | Inhibitory | Decreased | Decreased | - | - |
| VGLUT1 | Glutamate transporter | Excitatory | Reduced | Reduced | Reduced | - |
| Gephyrin | Inhibitory scaffold | Inhibitory | Reduced | - | Reduced | - |
| Neurexin | Presynaptic adhesion | All | Dysregulated | Dysregulated | Mutated | - |
| Neuroligin | Postsynaptic adhesion | All | Dysregulated | Dysregulated | Mutated | - |

Additional Research

Molecular Mechanisms

Oxidative stress involves multiple interconnected pathways:

Disease Relevance

• Alzheimer's: Aβ induces oxidative stress; antioxidants show protective effects[29].
• Parkinson's: Substantia nigra is particularly vulnerable to oxidative damage[30].
• ALS: Motor neurons have high metabolic demand and ROS production[31].
• HD: Mutant huntingtin impairs mitochondrial function[32].

See Also

• [Synaptic Vesicle Trafficking — Vesicle cycle details](/mechanisms/synaptic-vesicle-trafficking)
• [Excitotoxicity — Pathological glutamate signaling](/entities/glutamate)
• [Calcium Dysregulation — Calcium-dependent mechanisms](/content/mechanisms)
• [Dopaminergic Neurodegeneration — DA synapse failure](/entities/dopamine)
• [Alzheimer's Disease — Synaptopathy paradigm](/diseases/alzheimers-disease)

External Links

• [Allen Brain Atlas Synaptic Gene Expression](https://human.brain-map.org/)
• [SynGO Synaptic Gene Ontology](https://www.syngoportal.org/)

Recent Research Updates (2024-2026)

• [HK et al. 2024: The Trigeminal Sensory System and Orofacial Pain.](https://pubmed.ncbi.nlm.nih.gov/39457088/)
• [Y et al. 2025: Ppp2r1a haploinsufficiency increases excitatory synaptic transmission ](https://pubmed.ncbi.nlm.nih.gov/40839403/)
• [JM et al. 2024: Physiological Integration of Taste and Metabolism.](https://pubmed.ncbi.nlm.nih.gov/38718360/)
• [Y et al. 2024: BLA DBS improves anxiety and fear by correcting weakened synaptic tran](https://pubmed.ncbi.nlm.nih.gov/38349792/)
• [FC et al. 2024: A vagus nerve dominant tetra-synaptic ascending pathway for gastric pa](https://pubmed.ncbi.nlm.nih.gov/39537596/)

Neurotransmitter Systems in Neurodegeneration

The major neurotransmitter systems exhibit distinct patterns of dysfunction in neurodegenerative diseases:

Glutamatergic System

Glutamate is the primary excitatory neurotransmitter in the central nervous system, released at approximately 80% of cortical synapses[@sheng2007]. It acts on three classes of receptors:

• Ionotropic receptors: AMPA, NMDA, and kainate receptors, which are ligand-gated cation channels
• Metabotropic receptors: Eight mGluR subtypes (mGluR1-8) grouped into three functional classes

GABAergic System

GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter, released by interneurons that regulate excitatory circuits[@malenka2004]. In AD, GABAergic interneuron dysfunction contributes to:

• Network hyperexcitability
• Impaired gamma oscillations
• Memory encoding deficits
• Seizure susceptibility

Dopaminergic System

Dopamine is critical for motor control, reward, and cognitive function[@selkoe2002]. In PD:

• Progressive loss of substantia nigra dopaminergic neurons
• Motor symptoms correlate with >70% striatal dopamine depletion
• Non-motor symptoms involve mesocortical and mesolimbic pathways

Cholinergic System

The cholinergic system is essential for attention, memory, and learning:

• Basal forebrain cholinergic neurons degenerate early in AD
• Cholinergic deficits correlate with cognitive impairment
• Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide symptomatic benefit

Synaptic Dysfunction in Neurodegenerative Diseases

Alzheimer's Disease

Synaptic loss is the strongest correlate of cognitive decline in AD, exceeding the predictive value of amyloid plaques or neurofibrillary tangles[@bhatt2014]. Mechanisms include:

Parkinson's Disease

Alpha-synuclein pathology affects synaptic function through:

Amyotrophic Lateral Sclerosis

Synaptic dysfunction in ALS includes:

Huntington's Disease

Mutant huntingtin affects synaptic function through:

Therapeutic Approaches

Synaptic Protection Strategies

| Target | Approach | Status |
|--------|----------|--------|
| Glutamate excitotoxicity | NMDA antagonists, AMPA antagonists | Memantine (FDA approved) |
| Synaptic vesicle function | Alpha-synuclein aggregation inhibitors | In development |
| SNARE complex stabilization | Syntaxin-1 modulators | Preclinical |
| Synaptic plasticity | NMDA receptor modulators | In development |

Synaptic Regeneration Approaches

References

Futur